CLONIDINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for clonidine hydrochloride and what is the scope of freedom to operate?

Clonidine hydrochloride is the generic ingredient in seven branded drugs marketed by Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Mylan Institutional, Azurity, Tris Pharma Inc, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Chartwell Rx, Jubilant Generics, Novast Labs, Ph Health, Rubicon Research, Somerset Theraps Llc, Xiamen Lp Pharm Co, Concordia Pharms Inc, Boehringer Ingelheim, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Tp Anda Holdings, Unichem, Warner Chilcott, Watson Labs, and Yung Shin Pharm, and is included in fifty-nine NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Clonidine hydrochloride has twenty-one patent family members in fourteen countries.

There are thirteen drug master file entries for clonidine hydrochloride. Forty-two suppliers are listed for this compound.

Summary for CLONIDINE HYDROCHLORIDE

International Patents:	21
US Patents:	4
Tradenames:	7
Applicants:	37
NDAs:	59
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	42
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	425
Patent Applications:	4,427
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CLONIDINE HYDROCHLORIDE
What excipients (inactive ingredients) are in CLONIDINE HYDROCHLORIDE?	CLONIDINE HYDROCHLORIDE excipients list
DailyMed Link:	CLONIDINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CLONIDINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	PHASE3
Montefiore Medical Center	PHASE3
Wake Forest University Health Sciences	PHASE4

See all CLONIDINE HYDROCHLORIDE clinical trials

Pharmacology for CLONIDINE HYDROCHLORIDE

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

Anatomical Therapeutic Chemical (ATC) Classes for CLONIDINE HYDROCHLORIDE

C02AC	Imidazoline receptor agonists
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

N02CX	Other antimigraine preparations
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for CLONIDINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KAPVAY	Extended-release Tablets	clonidine hydrochloride	0.1 mg and 0.2 mg	022331	1	2011-03-04

US Patents and Regulatory Information for CLONIDINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET;ORAL	070886-003	Aug 31, 1988	AB	RX	No	No
Yung Shin Pharm	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET;ORAL	202297-003	Jun 13, 2013	AB	RX	No	No
Hikma Farmaceutica	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	INJECTABLE;INJECTION	200300-002	Jan 26, 2011	AP	RX	No	Yes
Chartwell Rx	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209285-001	Oct 23, 2017	AB1	RX	No	No

Expired US Patents for CLONIDINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-003	Approved Prior to Jan 1, 1982	3,454,701
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-001	Sep 30, 2009	5,869,100
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982	3,454,701
Concordia Pharms Inc	KAPVAY	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-004	Sep 28, 2010	5,869,100

International Patents for CLONIDINE HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Japan	5479086
Australia	2007227569	Modified release formulations containing drug-ion exchange resin complexes
Taiwan	200812649	Modified release formulations containing drug-ion exchange resin complexes
China	101400343	Modified release formulations containing drug-ion exchange resin complexes

Market Dynamics and Financial Trajectory for Clonidine Hydrochloride

Last updated: July 27, 2025

Introduction

Clonidine hydrochloride is a centrally acting alpha-2 adrenergic agonist primarily prescribed for hypertension management, but with expanding indications in ADHD, opioid withdrawal, and neuropathic pain. As a long-established pharmaceutical, its market dynamics are influenced by evolving clinical practices, patent landscapes, manufacturing trends, and competitive shifts within the antihypertensive and neurological therapeutic segments. This analysis evaluates the current market environment, growth drivers, challenges, and the projected financial trajectory for clonidine hydrochloride.

Pharmaceutical Overview of Clonidine Hydrochloride

Clonidine hydrochloride emerged in the 1970s as a potent antihypertensive agent and is available both as a tablet and transdermal patch. Its pharmacological profile includes sedative and anxiolytic properties, facilitating alternative therapeutic uses. The formulation landscape is dominated by generic manufacturers, with key players holding extensive production capacities.

Market Dynamics

1. Therapeutic Landscape and Clinical Demand

Clonidine remains relevant as a second-line antihypertensive agent, especially in resistant cases or where patients are intolerant to other medications. Its versatility extends to off-label applications such as ADHD management in pediatric populations, opioid withdrawal syndromes, and certain neuropathic pain conditions. The rising incidence of hypertension globally—in tandem with increased awareness—propels continued demand. Meanwhile, the expanding recognition of clonidine’s utility in ADHD, particularly as an adjunct therapy, further sustains its clinical relevance.

2. Competitive Environment and Genericization

The market for clonidine hydrochloride is heavily commoditized. Since patent expiration, multiple generic manufacturers have entered the space, intensifying price competition. Low-cost generics dominate markets across North America, Europe, and emerging economies. This commoditization limits profit margins but guarantees widespread availability. Patent cliffs for formulation patents have catalyzed market saturation, with the majority of revenues originating from generic sales.

3. Regulatory and Patent Trends

While original patents expired decades ago, ongoing patent applications cover specific formulations and delivery mechanisms, such as transdermal patches with improved adhesion or delivery efficiency. Regulatory approvals for new indications or formulations can temporarily bolster market dynamics. Conversely, regulatory scrutiny around off-label use and safety concerns, such as rebound hypertension upon abrupt withdrawal, influence prescribing patterns.

4. Manufacturing and Supply Chain Considerations

Clonidine’s synthesis involves efficient chemical processes, enabling large-scale production at low costs. However, supply chain disruptions—exacerbated during the COVID-19 pandemic—have underscored manufacturing vulnerabilities. Ensuring quality control remains paramount amid stringent regulatory standards, impacting financial stability.

5. Emerging Competition and Market Shift

Novel antihypertensives with improved safety profiles (e.g., azilsartan, sacubitril/valsartan) subtly encroach on clonidine’s market share. Additionally, alternative therapies for ADHD and opioid withdrawal (such as guanfacine, dexmedetomidine) influence prescribing choices, creating indirect competitive pressures.

6. Geographic Market Variations

Developed markets exhibit stable but mature demand, driven by well-established treatment guidelines. Conversely, emerging economies display growth potential due to increasing hypertension prevalence, expanding healthcare infrastructure, and growing acceptance of generic therapies. This geographic divergence shapes overall market strategy for manufacturers.

Financial Trajectory

1. Revenue Trends and Market Forecasts

Global sales of clonidine hydrochloride are characterized by incremental decline in some mature markets owing to generic competition but remain steady due to high-volume demand. According to IQVIA data, the antihypertensive segment attributed to clonidine is valued at approximately $200 million annually, with a compound annual growth rate (CAGR) hovering around 2-3% over the past five years [1].

Emerging markets could witness a CAGR of approximately 4-6%, driven by increasing hypertensive patient populations and healthcare expansion. The expansion of indications, notably in ADHD and opioid withdrawal, could further elevate revenues, although these accounts represent smaller segments currently.

2. Profitability and Pricing Dynamics

Generic commoditization has led to significant price erosion. Average retail prices in Western markets have declined sharply over the last decade, with some estimates indicating a 50% reduction. Manufacturers leveraging high-volume, low-margin strategies sustain profitability through scale, cost management, and process optimizations.

3. Investment in Innovation

While incremental innovations—such as novel transdermal delivery systems—could provide temporary market advantages, large-scale R&D initiatives are less prominent due to low profitability prospects. Strategic focus tends toward manufacturing efficiency and expanding clinical indications.

4. Impact of Regulatory Changes and Market Entry Barriers

Stringent quality standards and regulatory hurdles erect barriers to new entrants, preserving market share for established manufacturers. However, potential reformulations with enhanced safety profiles or fixed-dose combinations could stimulate modest revenue growth.

5. Future Outlook

Projections indicate a slow but steady decline in traditional formulations' revenues over the next decade, with potential stabilization or slight increase if new indications gain regulatory approval or if market expansion in emerging economies accelerates. The global clonidine hydrochloride market is expected to approach a valuation of approximately $150-180 million by 2030, factoring in market contraction in mature regions but growth in developing markets [2].

Challenges and Opportunities

Challenges

• Intense price competition compresses margins.
• Declining demand in mature markets due to evolving treatment guidelines favoring other antihypertensives.
• Safety concerns, such as rebound hypertension, may restrict off-label use.
• Supply chain vulnerabilities impacting global availability.

Opportunities

• Expansion into emerging markets with high hypertension prevalence.
• Development of new formulations or delivery systems improving compliance.
• Broader acceptance for off-label indications, contingent on supportive evidence.
• Strategic partnerships for manufacturing and distribution.

Conclusion

Clonidine hydrochloride's market remains fundamentally stable but faces structural headwinds from generic competition, evolving clinical preferences, and technological advancements. Its financial trajectory predicts modest growth in developing regions, with potential declines in saturated markets unless innovation or new indications invigorate interest. Stakeholders must navigate these dynamics prudently, balancing cost efficiencies with strategic product development.

---

Key Takeaways

• Market Maturity: Clonidine hydrochloride operates predominantly in mature, highly competitive markets with declining revenues in developed regions due to generic saturation.
• Demand Drivers: Rising hypertension prevalence globally, especially in emerging economies, sustains future growth, complemented by expanding indications in psychiatry and pain management.
• Pricing Pressure: Price erosion from generics limits profitability, necessitating operational efficiencies.
• Innovation Focus: Incremental formulation improvements and new delivery mechanisms present limited growth opportunities but can distinguish manufacturers.
• Strategic Expansion: Market expansion in low-penetration regions offers the most significant potential for revenue growth.

---

FAQs

1. What are the main therapeutic uses of clonidine hydrochloride?
   Primarily used for hypertension management, clonidine also treats ADHD, opioid withdrawal, and certain neuropathic pain conditions through off-label applications.

2. How does patent expiration affect the clonidine market?
   Patent expiration led to proliferation of generic manufacturing, intensifying price competition and reducing brand-name drug revenues.

3. What are major competitive threats to clonidine hydrochloride?
   Emerging antihypertensive agents with improved safety profiles, alternative ADHD therapies, and new formulations threaten market share.

4. What future growth opportunities exist for clonidine hydrochloride?
   Expansion into underserved markets, development of innovative delivery systems, and potential new indications could provide growth avenues.

5. How do regulatory factors influence clonidine’s market trajectory?
   Regulatory approvals for new formulations or indications can temporarily boost revenues; however, safety concerns and approvals decisions also impact the market.

---

References

[1] IQVIA. (2022). Global Pharmaceutical Market Reports.

[2] MarketResearch.com. (2023). Future Trends in the Antihypertensive Market.